Adam Yuh Lin, Joseph Michael Schnitter, Leo I Gordon
{"title":"治疗霍奇金淋巴瘤的免疫检查点阻断剂。","authors":"Adam Yuh Lin, Joseph Michael Schnitter, Leo I Gordon","doi":"10.2147/ITT.S284988","DOIUrl":null,"url":null,"abstract":"<p><p>Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line therapy. There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting. In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.</p>","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"11 ","pages":"1-10"},"PeriodicalIF":6.2000,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/a8/itt-11-1.PMC8882667.pdf","citationCount":"0","resultStr":"{\"title\":\"Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma.\",\"authors\":\"Adam Yuh Lin, Joseph Michael Schnitter, Leo I Gordon\",\"doi\":\"10.2147/ITT.S284988\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line therapy. There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting. In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.</p>\",\"PeriodicalId\":30986,\"journal\":{\"name\":\"ImmunoTargets and Therapy\",\"volume\":\"11 \",\"pages\":\"1-10\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2022-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/a8/itt-11-1.PMC8882667.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ImmunoTargets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ITT.S284988\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S284988","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
经典霍奇金淋巴瘤在生物学上与其他淋巴瘤不同。癌细胞只占据淋巴结的一小部分,并通过PD-L1和PD-L2的扩增来逃避免疫系统。因此,检查点抑制剂是霍奇金淋巴瘤患者释放免疫系统的合理治疗选择。检查点抑制剂在晚期霍奇金淋巴瘤的临床试验中显示出较高的应答率。最常用的两种检查点抑制剂是 pembrolizumab 和 nivolumab,这两种药物都被 FDA 批准作为三线疗法。检查点抑制剂与联合化疗或其他靶向药物一起用于二线甚至一线治疗的兴趣日益浓厚。在本综述中,我们将重点介绍导致霍奇金淋巴瘤检查点抑制剂获批的临床试验。
Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma.
Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line therapy. There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting. In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.
期刊介绍:
Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.